Modulation of β-adrenergic receptors in the ventromedial hypothalamus influences counterregulatory responses to hypoglycemia

32Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

OBJECTIVE - Norepinephrine is locally released into the ventromedial hypothalamus (VMH), a key brain glucose-sensing region in the response to hypoglycemia. As a result, this neurotransmitter may play a role in modulating counterregulatory responses. This study examines whether norepinephrine acts to promote glucose counterregulation via specific VMH b-adrenergic receptors (BAR). RESEARCH DESIGN AND METHODS - Awake male Sprague- Dawley rats received, via implanted guide cannulae, bilateral VMH microinjections of 1) artificial extracellular fluid, 2) B2AR agonist, or 3) B2AR antagonist. Subsequently, a hyperinsulinemic-hypoglycemic clamp study was performed. The same protocol was also used to assess the effect of VMH delivery of a selective B1AR or B3AR antagonist. RESULTS - Despite similar insulin and glucose concentrations during the clamp, activation of B2AR in the VMH significantly lowered by 32% (P < 0.01), whereas VMH B2AR blockade raised by 27% exogenous glucose requirements during hypoglycemia (P < 0.05) compared with the control study. These changes were associated with alternations in counterregulatory hormone release. Epinephrine responses throughout hypoglycemia were significantly increased by 50% when the B2AR agonist was delivered to the VMH (P < 0.01) and suppressed by 32% with the B2AR antagonist (P < 0.05). The glucagon response was also increased by B2AR activation by 63% (P < 0.01). Neither blockade of VMH B1AR nor B3AR suppressed counterregulatory responses to hypoglycemia. Indeed, the B1AR antagonist increased rather than decreased epinephrine release (P < 0.05). CONCLUSIONS - Local catecholamine release into the VMH enhances counterregulatory responses to hypoglycemia via stimulation of B2AR. These observations suggest that B2AR agonists might have therapeutic benefit in diabetic patients with defective glucose counterregulation. © 2011 by the American Diabetes Association.

References Powered by Scopus

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus

0
23986Citations
N/AReaders
Get full text

Hypoglycemia in the diabetes control and complications trial

0
1128Citations
N/AReaders
Get full text

Lack of glucagon response to hypoglycemia in diabetes: Evidence for an intrinsic pancreatic alpha cell defect

581Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Mechanisms of diabetic complications

2056Citations
N/AReaders
Get full text

Hypothalamic glucose sensing: Making ends meet

138Citations
N/AReaders
Get full text

Severe hypoglycemia-induced lethal cardiac arrhythmias are mediated by sympathoadrenal activation

119Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Szepietowska, B., Zhu, W., Chan, O., Horblitt, A., Dziura, J., & Sherwin, R. S. (2011). Modulation of β-adrenergic receptors in the ventromedial hypothalamus influences counterregulatory responses to hypoglycemia. Diabetes, 60(12), 3154–3158. https://doi.org/10.2337/db11-0432

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 14

58%

Researcher 6

25%

Professor / Associate Prof. 3

13%

Lecturer / Post doc 1

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 15

58%

Agricultural and Biological Sciences 7

27%

Pharmacology, Toxicology and Pharmaceut... 2

8%

Nursing and Health Professions 2

8%

Article Metrics

Tooltip
Mentions
News Mentions: 1
Social Media
Shares, Likes & Comments: 18

Save time finding and organizing research with Mendeley

Sign up for free